PolyPeptide Group AG Company Description

PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally.

It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products.

The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as well as development and analytical services.

The company serves academic, pharmaceutical, and biotech companies. PolyPeptide Group AG was founded in 1952 and is headquartered in Baar, Switzerland.

PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.

PolyPeptide Group AG

Country	Switzerland
Founded	1952
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	1,440
CEO	Juan Gonzalez

Contact Details

Address: Neuhofstrasse 24 Baar, 6340 Switzerland
Phone	41 435 020 580
Website	polypeptide.com

Stock Details

Ticker Symbol	PPGN
Exchange	SIX Swiss Exchange
Fiscal Year	January - December
Reporting Currency	EUR
ISIN Number	CH1110760852
SIC Code	8731

Key Executives

Name	Position
Juan Jose Gonzalez	Chief Executive Officer
Tim Brandl	Interim Chief Financial Officer and Director of Investor Relations, Financial Planning and Analysis
Rene Vestergaard	Director of Corporate Finance
Olivier Ludemann-Hombourger	Director of Global Innovation and Technology
Monika Casanova	Chief Human Resources Officer
Krister Svard	Chief Information Security Officer and Global IT Services VC
Rebecca Weil-Pflug	Head of Internal Audit
Stéphane Varray	Chief Commercial Officer
Inas Khedher	Head of Operations Controlling of Global Finance